Ovarian Folliculogenesis and Uterine Endometrial Receptivity after Intermittent Vaginal Injection of Recombinant Human Follicle-Stimulating Hormone in Infertile Women Receiving In Vitro Fertilization and in Immature Female Rats

• Published in: International journal of molecular sciences 2021-10, Vol.22 (19), p.10769
• Main Authors: Hsu, Chao-Chin, Hsu, Leonard, Hsueh, Yuan-Shuo, Lin, Chih-Ying, Chang, Hui Hua, Hsu, Chao-Tien
• Format: Article
• Language: English
• Subjects: Abdomen; endometrial receptivity; Endometrium; Follicle-stimulating hormone; Follicles; Folliculogenesis; Gametocytes; gonadotropin; In vitro fertilization; Infertility; Injection; Oocytes; ovarian folliculogenesis; Ovaries; Perfusion; Pharmacokinetics; Pharmacology; Pregnancy; Progesterone; Progesterone receptors; recombinant human follicle-stimulating hormone; Urine; uterine first-pass effect; Uterus; Vagina; vaginal administration; Womens health
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms221910769

The uterine first-pass effect occurs when drugs are delivered vaginally. However, the effect of vaginally administered recombinant human follicle-stimulating hormone (rhFSH) on ovarian folliculogenesis and endometrial receptivity is not well established. We aimed to compare the efficacy of rhFSH administered vaginally and abdominally in clinical in vitro fertilization (IVF) treatment, pharmacokinetic study, and animal study. In IVF treatment, the number of oocytes retrieved, endometrial thickness and uterine artery blood perfusion were not different between women who received the rhFSH either vaginally or abdominally. For serum pharmacokinetic parameters, significantly lower Tmax, clearance, and higher AUC and T1/2_elimination of rhFSH were observed in women who received rhFSH vaginally, but urine parameters were not different. Immature female rats that received daily abdominal or vaginal injections (1 IU twice daily for 4 days) or intermittent vaginal injections (4 IU every other day for two doses) of rhFSH had more total follicles than the control group. In addition, the serum progesterone and progesterone receptors in the local endometrium were significantly higher in the groups treated with intermittent abdominal or vaginal injection of rhFSH, compared with those who recieved daily injection. In summary, vaginal administration of rhFSH may provide an alternative treatment regimen in women receiving IVF.